Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Terns Pharmaceuticals, Inc. (TERN : NSDQ)

• Company Description    Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY, Calif. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $8.59 Daily Weekly Monthly 20 Day Moving Average: 1,595,861 shares Shares Outstanding: 87.51 (millions) Market Capitalization: $751.72 (millions) Beta: -0.03 52 Week High: $9.03 52 Week Low: $1.87 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.38% 11.02% 12 Week 41.28% 29.15% Year To Date 55.05% 32.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1065 EAST HILLSDALE BLVD. SUITE 100 - FOSTER CITY,CA 94404 USA ph: 650-525-5535 fax: - investors@ternspharma.com http://www.ternspharma.com

• General Corporate Information    Officers Amy Burroughs - Chief Executive Officer and Director David Fellows - Chairman of the Board of Directors Andrew Gengos - Chief Financial Officer Robert Azelby - Director Jeffrey Kindler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 880881107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 87.51 Most Recent Split Date: (:1) Beta: -0.03 Market Capitalization: $751.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.46 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 16.13% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -27.35 03/31/25 - -28.81 ROA 09/30/25 - - 06/30/25 - -26.18 03/31/25 - -27.55 Current Ratio 09/30/25 - - 06/30/25 - 24.70 03/31/25 - 30.89 Quick Ratio 09/30/25 - - 06/30/25 - 24.70 03/31/25 - 30.89 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 3.49 03/31/25 - 3.73 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©